Personalized Peptide Immunization Shows Promise in Advanced-Stage Prostate Cancer

Strategic Insights -

Researchers at the University of Munich have published a case report on a patient with advanced-stage prostate cancer who underwent personalized peptide-based immunization. According to the study, the patient received multiple injections of two peptide pools as a standalone therapy, resulting in a significant regression of both metastatic and primary tumor lesions, along with a low level of prostate-specific antigen (PSA). The treatment was well-tolerated, with only mild and short-lasting local and systemic reactions reported by the patient.

Key Takeaways:

  • The study reports a de novo metastatic hormone-sensitive prostate cancer (mHSPC) case that benefited from personalized peptide immunization as a monotherapeutic setting.
  • The patient received multiple injections of two peptide pools, named BioInformatic Tumor Address Peptides (BITAP-1 and BITAP-2), which were computationally predicted based on somatic variations and gene expression analysis.
  • The treatment resulted in a significant regression of both metastatic and primary tumor lesions, along with a low level of PSA.
  • The treatment was well-tolerated, with only mild and short-lasting local and systemic reactions reported by the patient.
  • The study suggests that personalized peptide immunization may induce sustainable tumor regressions in mHSPC patients.
  • The researchers involved in the study included Nils Heinrich Thoennissen, University of Munich, Medical Clinic III, Munich, Germany, and 5 additional authors.
  • The study was published in the journal Frontiers in Oncology, Volume 15, in 2025.

Statistics:

  • The patient received 2 peptide pools (BITAP-1 and BITAP-2) as standalone therapy.
  • The treatment resulted in a significant regression of both metastatic and primary tumor lesions.
  • The patient experienced only mild and short-lasting local and systemic reactions.
  • The PSA level lowered significantly after the treatment.

Sources:

  • Case Report: Personalized peptide-based immunization in an advanced-stage prostate cancer patient with bone metastasis. Frontiers in Oncology, 2025, 15.
  • Frontiers in Oncology (http://www.frontiersin.org/oncology)
  • Researchers Have Published New Study Findings on Prostate Cancer (Case Report: Personalized peptide-based immunization in an advanced-stage prostate cancer patient with bone metastasis). Vaccine Weekly. August 6, 2025; p 79.
  • University of Munich, Medical Clinic III, Munich, Germany.